INDICATIONS
Tablets and Suspensions
Urinary Tract Infections: For the treatment of urinary
tract infections due to susceptible strains of the following organisms:
Escherichia coli, Klebsiella species, Enterobacter species, Morganella
morganii, Proteus mirabilis and Proteus vulgaris. It is recommended
that initial episodes of uncomplicated urinary tract infections
be treated with a single effective antibacterial agent rather than
the combination.
Acute Otitis Media: For the treatment of acute otitis
media in pediatric patients due to susceptible strains of Streptococcus
pneumoniae or Haemophilus influenzae when, in the judgment of the
physician, sulfamethoxazole; trimethoprim offers some advantage
over the use of other antimicrobial agents. To date, there are limited
data on the safety of repeated use of sulfamethoxazole; trimethoprim
in pediatric patients under two years of age. Sulfamethoxazole;
trimethoprim is not indicated for prophylactic or prolonged administration
in otitis media at any age.
Acute Exacerbations of Chronic Bronchitis in Adults:
For the treatment of acute exacerbations of chronic bronchitis due
to susceptible strains of Streptococcus pneumoniae or Haemophilus
influenzae when, in the judgment of the physician, sulfamethoxazole;
trimethoprim offers some advantage over the use of a single antimicrobial
agent.
Pneumocystis Carinni Pneumonia: For the treatment
of documented Pneumocystis carinii pneumonia. For prophylaxis against
Pneumocystis carinni pneumonia in individuals who are immunosuppressed
and considered to be at an increased risk of developing Pneumocystis
carinni pneumonia.
Travelers' Diarrhea In Adults: For the treatment
of travelers' diarrhea due to susceptible strains of enterotoxigenic
E. coli.
Shigellosis: For the treatment of enteritis caused
by susceptible strains of Shigella flexneri and Shigella sonnei
when antibacterial therapy is indicated.
IV Infusion
Pneumocystis Carinii Pneumonia: Sulfamethoxazole;
trimethoprim IV is indicated in the treatment of Pneumocystis carinii
pneumonia in pediatric patients and in adults.
Shigellosis: Sulfamethoxazole; trimethoprim IV is
indicated in the treatment of enteritis caused by susceptible strains
of Shigella flexneri and Shigella sonnei in pediatric patients and
adults.
Urinary Tract Infections: Sulfamethoxazole; trimethoprim
IV is indicated in the treatment of severe or complicated urinary
tract infections due to susceptible strains of Escherichia coli,
Klebsiella species, Enterobacter species, Morganella morganii and
Proteus species when oral administration of sulfamethoxazole; trimethoprim
is not feasible and when the organism is not susceptible to single-agent
antibacterials effective in the urinary tract.
Although appropriate culture and susceptibility studies
should be performed, therapy may be started while awaiting the results
of these studies.
DOSAGE AND ADMINISTRATION
Tablets and Suspensions
Contraindicated in pediatric patients less than two
months of age.
Urinary Tract Infections and Shigellosis in Adults
and Pediatric Patients, and Acute Otitis Media in Pediatric Patients
Adults: The usual adult dosage in the treatment of
urinary tract infections is one sulfamethoxazole; trimethoprim DS
(double strength) tablet, two sulfamethoxazole; trimethoprim tablets,
or 4 teaspoonfuls (20 ml) of sulfamethoxazole; trimethoprim suspensions
every 12 hours for 10 to 14 days. An identical daily dosage is used
for 5 days in the treatment of shigellosis.
Pediatric Patients: The recommended dose for pediatric
patients with urinary tract infections or acute otitis media is
8 mg/kg trimethoprim and 40 mg/kg sulfamethoxazole per 24 hours,
given in 2 divided doses every 12 hours for 10 days. An identical
daily dosage is used for 5 days in the treatment of shigellosis.
TABLE 3 is a guideline for the attainment of this dosage.
|
